UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, DC 20549　

FORM 8-K

~~Current~~CURRENT ~~Report Pursuant~~REPORT

Pursuant to Section 　13 or 15(d) of ~~the~~The Securities Exchange Act of 1934

~~Securities~~Date ~~Exchange~~of ~~Act~~Report (Date of ~~1934~~earliest event reported): July 20, 2010

Date of Report: March 2, 2009

PULMO BIOTECH INC.

(Exact name of ~~Registrant~~registrant as specified in its charter)

Delaware 000-50678 20-5622985 (State or other jurisdiction of incorporation) (Commission File No.) (I.R.S. Employer Identification No.)

Delaware		000-50678		20-5622985
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1035 Park Avenue, Suite 7B

New York, NYNew York 10028-0912

(Address of ~~Principal~~principal ~~Executive~~executive ~~Offices~~offices, including zip code)

(646) 827-9362

(Registrant's telephone number, including area code)

~~Item~~Check ~~7.01.~~the ~~Regulation~~appropriate FDbox ~~Disclosure~~below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

On[ ~~March~~] 2,Written ~~2009,~~communications ~~Pulmo~~pursuant ~~BioTech Inc., a Delaware corporation, released a press release in which it announced its successful completion of all of the experimental work required for Regulatory Approval~~ to ~~commence~~Rule ~~Phase~~425 ~~I Human~~under ~~Trials of its product candidate for~~ the ~~PulmoBind~~Securities ~~technology of Molecular~~Act ~~Imaging~~ (17 ofCFR ~~the vascular system of the lungs~~230. ~~A copy of the release is attached hereto as Exhibit 99.1.~~425)

~~Item~~[ ~~9.01.~~] ~~Financial~~Soliciting ~~Statements~~material ~~and~~pursuant ~~Exhibits~~to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(ab) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(bc) ~~Pro~~under ~~Forma~~the Exchange ~~Financial~~Act ~~Information~~(17 CFR 240.13e-4(c))

~~(c)~~Item ~~Shell~~5.02. ~~Company~~Departure ~~Transactions~~of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

~~(d)~~Ian ~~Exhibits~~Ilsley resigned as a Director on July 20, 2010, leaving Garry McCann as the sole remaining member of the Board of Directors.

~~99 Press Release dated March 2, 2009.~~SIGNATURE

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Pursuant~~Date: toJuly ~~the requirements of the Securities Exchange Act of 1934~~20, ~~the~~2010 ~~registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~

PULMO BIOTECH INC. By: /s/ ~~Garry~~ ~~McCann Name:~~Peter ~~Garry~~B. ~~McCann Title:~~Hirshfield________ ~~President~~Peter ~~and~~B. ~~Chief Executive Officer~~ Hirshfield.

Filing Compare · PULMO BIOTECH INC.